Evenovia Shares Are Trading Higher After the Company Announced It Will Present Results From Its Successful Phase 3 CPN-302 Study of Clobetasol Propionate Suspension 0.05% as a Treatment for Inflammation and Pain Following Ocular Surgery. The Results...

Benzinga · Oct 17 02:03

Evenovia Shares Are Trading Higher After the Company Announced It Will Present Results From Its Successful Phase 3 CPN-302 Study of Clobetasol Propionate Suspension 0.05% as a Treatment for Inflammation and Pain Following Ocular Surgery. The Results Will Be Presented at the American Academy of Ophthalmology 2024 Expo.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Evenovia Shares Are Trading Higher After the Company Announced It Will Present Results From Its Successful Phase 3 CPN-302 Study of Clobetasol Propionate Suspension 0.05% as a Treatment for Inflammation and Pain Following Ocular Surgery. The Results...

Risk Disclaimer